CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
CERo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CERo Therapeutics's operating cash flow for the twelve months ending Dec 31, 2023 was -$1.52M. For fiscal 2025 it was -$16.10M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.10M | – |
| FY2023 | Dec 31, 2023 | -$1.52M | – |
| FY2022 | Dec 31, 2022 | -$1.09M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.89M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$186.61K | – |
| Q3 FY2023 | Sep 30, 2023 | -$256.12K | – |
| Q2 FY2023 | Jun 30, 2023 | -$883.10K | – |
| Q1 FY2023 | Mar 31, 2023 | -$197.78K | – |
| Q4 FY2022 | Dec 31, 2022 | -$373.10K | – |
| Q3 FY2022 | Sep 30, 2022 | -$174.35K | – |
| Q2 FY2022 | Jun 30, 2022 | -$236.71K | – |
| Q1 FY2022 | Mar 31, 2022 | -$308.09K | – |
See a number that looks wrong?